Home › Atrial Fibrillation › Georgia › Johns Creek
Atrial Fibrillation clinical trials in Johns Creek, GA
4 studies for Atrial Fibrillation are looking for participants at sites in and around Johns Creek (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
RecruitingPhase 3
- NSC Research, Inc, Johns Creek
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
RecruitingPhase 2
- NSC Research, Inc, Johns Creek
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
RecruitingPhase 3
- NSC Research, Inc, Johns Creek
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
RecruitingPhase 3
- Anthos Investigative Site 1003, Suwanee · 7 mi away
About Atrial Fibrillation
Atrial fibrillation (AF or AFib) is the most common type of arrhythmia (irregular heartbeat). Read about symptoms and treatment.
More about Atrial Fibrillation on MedlinePlus
Atrial Fibrillation trials in other cities
- New York City, NY21 studies
- Cleveland, OH17 studies
- Boston, MA17 studies
- Atlanta, GA16 studies
- Jonesboro, AR12 studies
- Chicago, IL12 studies
- Philadelphia, PA12 studies
- Ann Arbor, MI11 studies
- Cincinnati, OH10 studies
- Columbus, OH10 studies
- Pittsburgh, PA10 studies
- Austin, TX9 studies
Other studies in Johns Creek
- Obesity16 studies
- Overweight14 studies
- Schizophrenia8 studies
- Type 2 Diabetes8 studies
- Major Depressive Disorder7 studies
- Lung Cancer6 studies
- Heart Failure5 studies
- Non-Small Cell Lung Cancer5 studies
- Breast Cancer4 studies
- High Blood Pressure4 studies
- Coronary Artery Disease3 studies
- Cholesterol3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.